Endocannabinoid System Overactivity in Obesity

CB1 receptor overactivation: In obesity, CB1 (cannabinoid receptor type 1) tends to be overstimulated. This increases appetite, enhances the rewarding effects of food, promotes fat storage, and reduces energy expenditure.

Elevated endocannabinoids: Molecules like anandamide (AEA) and 2-AG are often found in higher levels in obese individuals.

Peripheral effects: Beyond the brain, CB1 activation in the liver promotes lipogenesis (fat creation), in the pancreas it impairs insulin secretion, and in skeletal muscle it reduces glucose uptake—all of which worsen metabolic dysfunction.

Role of CBD in ECS Regulation

CBD as a “modulator”: Cannabidiol (CBD) does not directly activate or block CB1 like THC. Instead, CBD appears to indirectly influence receptor activity and may increase levels of endocannabinoids in a more balanced way by inhibiting their breakdown.

Receptor interactions: CBD also interacts with non-cannabinoid receptors (e.g., serotonin 5-HT1A, TRPV1, PPARγ), which may contribute to its effects on inflammation, metabolism, and mood.

Preclinical studies: Animal research suggests CBD can reduce appetite, modulate fat browning, improve insulin sensitivity, and reduce inflammation—all of which could counteract metabolic dysfunction.

Human data: Evidence in people is still limited and mixed. Some small studies suggest CBD may help with insulin resistance and appetite regulation, but we don’t yet have large-scale clinical trials confirming its role in weight management.

So where does that leave us?

The ECS is indeed central to energy balance and metabolic health, and its dysregulation in obesity makes it an attractive therapeutic target.

Researchers are interested in CBD and other cannabinoids because they might help “re-tune” the system.

However, CBD alone is unlikely to be a magic bullet—it may work best as part of a broader approach involving diet, exercise, as well as other metabolic therapies.

Akurati S, Hanlon EC. Beyond the Scale: Exploring the Endocannabinoid System’s Impact on Obesity. Curr Diab Rep. 2024;25(1):6. Published 2024 Nov 15. doi:10.1007/s11892-024-01562-2